Edition:
United States

Eli Lilly and Co (LLY)

LLY on New York Consolidated

84.18USD
24 Mar 2017
Change (% chg)

$-0.24 (-0.28%)
Prev Close
$84.42
Open
$84.30
Day's High
$84.98
Day's Low
$83.86
Volume
2,479,097
Avg. Vol
5,371,605
52-wk High
$86.14
52-wk Low
$64.18

Latest Key Developments (Source: Significant Developments)

Eli Lilly announces $850 mln investment in U.S. capital projects in 2017
Friday, 24 Mar 2017 08:00am EDT 

Eli Lilly And Co : Lilly announces $850 million investment in U.S. capital projects in 2017 . During 2012-2016, had increased U.S manufacturing workforce by more than 1,000 employees-from 5,000 to 6,000 roles-with about 400 added in Indianapolis . Company's investments span facilities across its U.S. Enterprise . Expansion is part of five-year investment by company to expand its diabetes products manufacturing operations in U.S. . Plans for a new $85 million expansion of its Trulicity (Dulaglutide) device assembly operations in U.S. . "On a path to launch 20 new products in a 10-year time frame" . Significant investment in manufacturing diabetes medicines continues with new $85 million commitment in indianapolis . Eli Lilly and Co says more favorable tax climate could lead to additional U.S. investments .Expansion also includes a $140 million insulin cartridge production facility.  Full Article

Ignyta to explore strategic options for Taladegib through amendment of Taladegib license agreement with Lilly
Thursday, 23 Mar 2017 04:00pm EDT 

Ignyta Inc : Ignyta announces exploration of strategic options for Taladegib, enabled by amendment of Taladegib license agreement with Lilly . Ignyta - agreement amends and restates prior license, development and commercialization agreement, dated November 6, 2015, by and between Ignyta, Lilly .Ignyta Inc - entered into amended , restated license, development, commercialization agreement with Eli Lilly and company for Taladegib Oncology program.  Full Article

Lilly says phase 3 breast cancer study meets primary endpoint
Monday, 20 Mar 2017 06:45am EDT 

Eli Lilly And Co : Lilly announces phase 3 monarch 2 breast cancer study of abemaciclib met primary endpoint of progression-free survival . Eli Lilly And Co - its monarch 2 trial of abemaciclib met primary endpoint of progression-free survival (pfs) . Eli Lilly And Co- intends to submit a new drug application (nda) for single-agent abemaciclib in q2 of 2017 .Plans to submit an additional application for monarch 2 in q3 of this year.  Full Article

Eli Lilly says senior VP of corporate affairs and communications to leave
Thursday, 2 Mar 2017 06:45am EST 

Eli Lilly And Co : Lilly announces changes in senior management . Eli Lilly and Co - Johna Norton will be promoted to senior vice president of global quality April 1, replacing Fionnuala Walsh . Eli Lilly And Co - Bart Peterson, senior vice president of corporate affairs and communications, will leave Lilly March 31 .Eli Lilly And Co - search currently is under way for Peterson's replacement.  Full Article

Perrigo announces FDA final approval for the generic version of Axiron topical solution
Wednesday, 1 Mar 2017 08:55am EST 

Perrigo Company Plc :Perrigo announces FDA final approval for the generic version of Axiron topical solution, 30 mg/1.5 ml.  Full Article

Lilly says provisions included in legislation to repeal Affordable Care Act could adversely affect results
Tuesday, 21 Feb 2017 03:44pm EST 

Eli Lilly And Co :Provisions included in legislation repealing, replacing affordable care act could have material adverse effect on consolidated results, cash flows.  Full Article

Lilly announces label update for its diabetes drug Trulicity
Wednesday, 8 Feb 2017 06:45am EST 

Eli Lilly And Co - : Lilly's Trulicity (dulaglutide) label updated to include use in combination with basal insulin for adults with type 2 diabetes .Label for once-weekly trulicity is now updated to include use in combination with basal insulin for adults with type 2 diabetes.  Full Article

Lilly reports Q4 EPS $0.73
Tuesday, 31 Jan 2017 06:25am EST 

Eli Lilly And Co : Lilly reports fourth-quarter and full-year 2016 results . Sees FY 2017 earnings per share $2.69 to $2.79 . Q4 earnings per share $0.73 . Q4 revenue $5.76 billion versus I/B/E/S view $5.55 billion . Q4 earnings per share view $0.98 -- Thomson Reuters I/B/E/S . Sees FY 2017 non-gaap earnings per share $4.05 to $4.15 . Sees FY 2017 revenue $21.8 billion to $22.3 billion . For Q4 of 2016, alimta generated worldwide revenue of $541.6 million, which decreased 14 percent compared with Q4 of 2015 . FY2017 earnings per share view $4.10, revenue view $21.96 billion -- Thomson Reuters I/B/E/S . Qtrly Cymbalta sales $181.8 million versus $223.6 million . Q4 non-GAAP earnings per share 0.95 . Worldwide Jardiance revenue during Q4 of 2016 was $76.1 million . In Q4 of 2016, company recognized asset impairment, restructuring and other special charges of $147.6 million .Asset impairment, restructuring charges in quarter associated with costs related to acquisition of Novartis Animal Health.  Full Article

Jaguar Animal Health, Elanco US to license, develop, and commercialize Canalevia
Tuesday, 31 Jan 2017 05:00am EST 

Jaguar Animal Health Inc :Jaguar Animal Health - co and Elanco US enter agreement to license, develop, and commercialize Canalevia.  Full Article

EMA recommends approval of two biosimilars from Amgen
Friday, 27 Jan 2017 07:21am EST 

European Medicines Agency : EU Medicines Agency recommendations for January 2017 . EU Medicines Agency recommends approval of Amgen's Amgevita and Solymbic, both containing adalimumab . EU Medicines Agency recommends approval of Tadalafil Lilly for treatment of erectile dysfunction and signs, symptoms of benign prostatic hyperplasia . EU Medicines Agency's CHMP offers positive opinion for Rolufta for the treatment of chronic obstructive pulmonary disease .EU Medicines Agency - Jylamvo (methotrexate) received a positive opinion for the treatment of rheumatological disorders and psoriasis, and for maintenance treatment of ALL.  Full Article

More From Around the Web

BRIEF-Eli Lilly and Co says CEO John Lechleiter's 2016 total compensation was $18.4 mln

* CEO John C. Lechleiter's 2016 total compensation was $18.4 million versus $16.6 million in 2015